Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapse Prevention Study of Vilazodone in Major Depressive Disorder
2012-001950-25Phase 3Completed
- Sponsor
- Forest Research Institute
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Vilazodone with Placebo (2 arms). Primary endpoint: Time to first relapse. Started Nov 2012; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2012-001950-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001950-25.